Publications by authors named "M Neuvonen"
In vitro evidence shows that the acyl--D-glucuronide metabolite of candesartan inhibits cytochrome P450 (CYP) 2C8 with an inhibition constant of 7.12 M. We investigated the effect of candesartan on the plasma concentrations and glucose-lowering effect of repaglinide, a sensitive clinical CYP2C8 index substrate.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied how different genetic variations in the CYP2D6 enzyme affect the body's ability to metabolize codeine into morphine, which is vital for determining pain relief and potential side effects.
- A clinical trial involving 1000 patients was conducted, where their CYP2D6 genotypes were analyzed after they were given a standard dose of codeine, and the relationship between their genetic makeup and morphine exposure was modeled.
- The results showed that individuals with certain genetic variations (like CYP2D6*10 and *41) had less effective metabolism of codeine, leading to significantly higher or lower morphine levels in the bloodstream, highlighting the importance of genetic testing for safer opioid prescribing.
Objective: This study aimed to evaluate the cytochrome P450 (CYP)-mediated drug-drug interaction (DDI) potential of kinase inhibitors with warfarin and direct oral anticoagulants (DOACs).
Methods: An in vitro CYP probe substrate cocktail assay was used to study the inhibitory effects of fifteen kinase inhibitors on CYP2C9, 3A, and 1A2. Then, DDI predictions were performed using both mechanistic static and physiologically-based pharmacokinetic (PBPK) models.
Background And Aims: Gallstone disease (GSD) associates with significant morbidity and mortality. Decreased secretion of bile acids has been suggested as a driving factor for GSD. Recently, we linked the protein phosphatase 1 regulatory subunit 3 beta ( rs4240624 genotype to decreased bile acid levels in bile.
View Article and Find Full Text PDFRiboflavin (vitamin B) has been proposed as a biomarker for breast cancer resistance protein (BCRP) activity. In recent studies in mice, cynomolgus monkeys, and humans, BCRP-inhibiting drugs increased the plasma concentration of riboflavin. We showed recently that ticagrelor inhibits BCRP and raises the plasma concentrations of the BCRP substrate rosuvastatin in healthy volunteers.
View Article and Find Full Text PDF